ACADIA Pharmaceuticals Inc (ACAD)
Liquidity ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 2.38 | 2.29 | 2.16 | 2.04 | 2.42 | 2.38 | 2.62 | 2.24 | 4.04 | 4.47 | 4.53 | 4.53 | 6.43 | 7.27 | 6.77 | 6.16 | 6.77 | 7.95 | 8.51 | 7.26 |
| Quick ratio | 1.91 | 1.64 | 1.48 | 1.42 | 1.73 | 1.65 | 2.00 | 1.80 | 3.32 | 3.75 | 3.71 | 3.73 | 5.42 | 6.12 | 5.84 | 5.28 | 5.96 | 7.02 | 7.62 | 6.53 |
| Cash ratio | 1.91 | 1.64 | 1.48 | 1.42 | 1.73 | 1.65 | 2.00 | 1.80 | 3.32 | 3.75 | 3.71 | 3.73 | 5.42 | 6.12 | 5.84 | 5.28 | 5.96 | 7.02 | 7.62 | 6.53 |
ACADIA Pharmaceuticals Inc's liquidity ratios, specifically the current ratio, quick ratio, and cash ratio, have exhibited a decline over the period from March 31, 2020, to December 31, 2024.
- The current ratio, which measures the company's ability to meet short-term obligations with its current assets, peaked at 8.51 on June 30, 2020, but decreased to 2.38 by December 31, 2024. This downward trend indicates a potential weakening in the company's short-term liquidity position.
- The quick ratio, which provides a more stringent measure of liquidity by excluding inventory from current assets, followed a similar pattern. It decreased from 7.62 on June 30, 2020, to 1.91 by December 31, 2024. This suggests a diminishing ability to cover immediate liabilities without relying on inventory.
- The cash ratio, which focuses solely on the company's ability to cover short-term liabilities with cash and cash equivalents, also showed a declining trend. It decreased from 7.62 on June 30, 2020, to 1.91 by December 31, 2024, indicating a decreasing ability to settle short-term obligations with cash on hand.
Overall, the decreasing trend in these liquidity ratios for ACADIA Pharmaceuticals Inc raises concerns about its short-term liquidity position and highlights the importance of monitoring its ability to meet upcoming financial obligations.
Additional liquidity measure
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash conversion cycle | days | 97.89 | 285.90 | 354.26 | 359.27 | 313.98 | 289.76 | 245.53 | 250.44 | 238.26 | 206.81 | 155.41 | 147.04 | 150.28 | 239.14 | 196.84 | 185.69 | 171.97 | 141.49 | 110.72 | 115.35 |
The cash conversion cycle of ACADIA Pharmaceuticals Inc has shown fluctuations over the periods analyzed. It ranged from a low of 97.89 days on December 31, 2024, to a high of 359.27 days on March 31, 2024. The cycle measures the time it takes for the company to convert its investments in inventory and other resources into cash flows from sales.
A shorter cash conversion cycle indicates that the company is able to quickly convert its investments into cash, which is a positive sign of operational efficiency. Conversely, a longer cycle suggests that the company may be facing challenges in turning its investments into cash, potentially leading to liquidity issues.
Overall, ACADIA Pharmaceuticals Inc's cash conversion cycle has displayed variability, and it's crucial for stakeholders to closely monitor this metric to assess the company's management of working capital and operational effectiveness.